| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.89 | $53.18 (0%) | 🛒 Add to cart |
| 90 | $0.81 | $79.77 $73.25 (8%) | 🛒 Add to cart |
| 120 | $0.78 | $106.36 $93.32 (12%) | 🛒 Add to cart |
| 180 | $0.75 | $159.54 $134.46 (16%) | 🛒 Add to cart |
| 270 | $0.72 | $239.31 $194.66 (19%) | 🛒 Add to cart |
| 360 | $0.71
Best per pill | $319.08 $254.87 (20%) | 🛒 Add to cart |
Synonyms | |||
Similar products
More info:
trazodone
Trazodone hydrochloride is a triazolopyridine derivative antidepressant medication that’s been in clinical use since the 1980s, initially approved for major depressive disorder but now widely utilized off-label for insomnia, particularly in patients where traditional hypnotics pose addiction risks. What’s fascinating about trazodone is how its clinical applications have evolved far beyond its original antidepressant indication - we’re now seeing it prescribed more frequently for sleep than for depression in many practices.
desyrel
Desyrel, known generically as trazodone hydrochloride, presents one of the more interesting paradoxes in modern psychopharmacology. Initially developed and approved as an antidepressant, its clinical utility has dramatically expanded off-label, particularly for managing insomnia—even becoming a first-line option for many sleep specialists despite lacking formal FDA approval for this indication. What began as a novel serotonin antagonist and reuptake inhibitor (SARI) has evolved into one of psychiatry’s most versatile tools, bridging the gap between traditional sleep aids and full-spectrum antidepressants.
Keppra: Effective Seizure Control with Favorable Safety Profile - Evidence-Based Review
Levetiracetam, marketed under the brand name Keppra among others, is a second-generation antiepileptic drug (AED) belonging to the racetam class. It’s a pyrrolidine derivative chemically unrelated to other AEDs, which actually gives it some unique advantages we’ll discuss. The drug exists as a white to off-white crystalline powder with high solubility, and it’s available in multiple formulations including immediate-release tablets (250 mg, 500 mg, 750 mg, 1000 mg), oral solution (100 mg/mL), and intravenous injection (100 mg/mL).
prothiaden
Prothiaden represents one of those older antidepressants that somehow keeps showing up in my complex depression cases, especially when newer agents fail. It’s the brand name for dothiepin, a tricyclic antidepressant (TCA) that’s been around since the 1960s but still has very specific clinical applications that many younger clinicians overlook. We actually had a departmental debate just last month about whether we should even keep it on our hospital formulary given the newer options available - I argued strongly for its retention based on some difficult treatment-resistant cases.
Sinequan: Potent Sleep and Mood Support for Insomnia and Depression - Evidence-Based Review
Sinequan, known generically as doxepin, is a tricyclic antidepressant (TCA) that has been a cornerstone in psychopharmacology for decades. Initially approved for depression and anxiety, its utility has expanded significantly due to its potent histamine H1 receptor antagonism, making it one of the most effective agents for insomnia, particularly sleep maintenance. Available in both oral concentrate and capsule forms, its versatility in dosing—from low-dose for sleep to higher doses for mood disorders—underscores its importance.
Tofranil: Multimodal Therapeutic Agent for Depression and Beyond - Evidence-Based Review
Imipramine hydrochloride, marketed under the brand name Tofranil, represents one of the foundational tricyclic antidepressants (TCAs) in clinical psychopharmacology. First synthesized in the late 1950s, it fundamentally shifted depression treatment paradigms away from electroconvulsive therapy and amphetamines toward neurotransmitter modulation. The drug exists primarily in 10mg, 25mg, and 50mg oral tablets, though parenteral formulations were historically available for hospital use. What’s fascinating about Tofranil isn’t just its antidepressant properties—it’s the unexpected therapeutic applications we’ve discovered over decades of clinical use, particularly in pediatric enuresis and neuropathic pain conditions that often get overlooked in modern SSRI-focused discussions.
abana
Product Description Abana represents one of those formulations that initially puzzled me when I first encountered it in practice - a comprehensive herbal supplement with roots in Ayurvedic medicine, primarily indicated for cardiovascular support. What struck me during my early years at the Cleveland Clinic was how this multi-herb preparation kept appearing in patients’ medication lists, particularly among those with familial hyperlipidemia patterns. The formulation contains a sophisticated blend of Terminalia arjuna, Inula racemosa, Commiphora mukul, and several other botanicals that work synergistically - something we rarely see in single-component pharmaceuticals.
abhigra
Product Description: Abhigra represents a novel class of medical-grade nutraceutical devices that combines standardized botanical extracts with a patented sublingual delivery system. Unlike conventional supplements, its mechanism relies on transmucosal absorption bypassing first-pass metabolism, which we’ve observed yields significantly faster onset of action—particularly valuable for acute inflammatory episodes. The development team spent three years battling stability issues with the nanoemulsion matrix before discovering that alternating temperature cycles during production actually enhanced bioactive preservation, contrary to our initial assumptions.
abilify
Aripiprazole, marketed under the brand name Abilify, represents a significant advancement in psychopharmacology as a second-generation antipsychotic medication. Unlike first-generation antipsychotics that primarily function as dopamine D2 receptor antagonists, aripiprazole exhibits a unique mechanism as a partial dopamine agonist. This pharmacological profile allows it to stabilize dopamine activity rather than simply blocking it, creating what many clinicians describe as a “dopamine stabilizer” effect. The medication has received FDA approval for multiple psychiatric conditions including schizophrenia, bipolar disorder, major depressive disorder (as adjunct treatment), Tourette’s disorder, and irritability associated with autistic disorder.